Honey preparation in complex therapy of metabolically associated fatty liver disease

The aim of the article. Evaluation of the clinical effectiveness of the natural honey drug Metrop GP in patients with metabolically associated fatty liver disease (MAFLD). Materials and methods. A prospective randomized open multi-center study was conducted. 70 patients aged 39 to 55 years with an established diagnosis of MAFLD were included. The study group consisted of 40 patients, the control group - 30 patients. All patients received drug therapy with the hepatoprotective drug S-ademetionine. Patients in the study group were also prescribed a 10-day course of Metrop GP therapy. For a detailed assessment of the effect of the honey preparation, all subjects were divided into subgroups depending on the genesis of MAFLD: obesity/type 2 diabetes mellitus (DM2)/metabolic syndrome (MS). The dynamics of complaints was assessed. The effect of the Metrop GP on biochemical blood parameters (indicators of liver cytolysis and cholestasis, carbohydrate and lipid metabolism) and oxidative stress markers was studied. The dynamics of all indicators were assessed twice (before the study and 2 weeks after the 10-day course of treatment with Metrop GP). Non-invasive assessment of liver steatosis and fibrosis was performed using the FibroMax serological test once before the start of therapy. The study was approved by the ethics committee of Union Clinic LLC (St. Petersburg). Protocol No. 1-06/2023 dated June 6, 2023. All patients in the study group signed voluntary informed consent to conduct the study. Statistical processing of the results was carried out using SPSS 26 for Windows. Differences were considered significant at a significance level of p<0.05 (95%). Results. According to the results obtained at the end of the study, patients receiving additional Metrop GP as part of complex therapy showed a statistically significant improvement in laboratory parameters of the indices of liver cytolysis, lipid metabolism and antioxidant status, which was not achieved in the comparison subgroups. In patients with MAFLD and type 2 diabetes, a significant decrease in glucose levels was also noted during the study therapy, in contrast to the control subgroup. Patients from all study groups noted an improvement in general well-being and a decrease in dyspeptic symptoms, but without significant differences. The study drug was well tolerated. Conclusion. The addition of the hepatoprotector Metrop GP to the treatment of MAFLD leads to an improvement in lipid metabolism, normalization of the indices of liver cytolysis and the body’s antioxidant system.

metabolically associated liver disease, hepatoprotector, honey preparation

1. Younossi Z.M., Koenig A.B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. doi: 10.1002/hep.28431.

2. Rong L., Zou J., Ran W., Qi X., Chen Y., Cui H., Guo J. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2023; 01 (16):13. doi: 10.3389/fendo.2022.1087260.

3. Polyzos S.A., Kountouras J., Mantzoros C.S. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019; 92:82-97. doi: 10.1016/j.metabol.2018.11.014.

4. Tanase D.M., Gosav E.M., Costea C.F., Ciocoiu M., Lacatusu C.M., Maranduca M.A., et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res. 2020; 07(31). doi: 10.1155/2020/3920196.

5. Muzurović E., Mikhailidis D.P., Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021; 01(119). doi: 10.1016/j.metabol.2021.154770.

6. Buzzetti E., Pinzani M., Tsochatzis E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016: 65(8):1038-1048. doi: 10.1016/j.metabol.2015.12.012.

7. Rinella M.E., Lazarus J.V., Ratziu V., Francque S.M., Sanyal A.J., Kanwal F. et al. NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520.

8. Demidova T.Y., Ushanova F.O. Non-alcoholic fatty liver disease: aspects of management of a comorbid patient. A review. Ter Arkh. 2023;23;95(10):888-895. (in Russ.) doi: 10.26442/00403660.2023.10.202435.

9. Abduloeva N. Kh., Kolbasov S. Ye., Stukov A.N., Moiseenko V.M. Preclinical evaluation of the effect of metrop gp on acute toxicity and hepatotoxicity of chemotherapy. Prob in oncol. 2011; 57(1):71-74. (In Russ.)@@ Абдулоева, Н. Х., Колбасов, С. Е., Стуков, А. Н., Моисеенко, В.М. Предклиническая оценка влияния препарата Метроп ГП на острую токсичность и гепатотоксичность химиотерапии. Вопр онкол. 2011; 57(1):71-74.

10. El H.H., Di V.A., Vettor R., Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease.Int J Mol Sci. 2019; 6;20(9):2215. doi: 10.3390/ijms20092215.

11. Ghosh A.K., Vaughan D.E. PAI-1 in tissue fibrosis. J Cell Physiol. 2012;227(2):493-507. doi: 10.1002/jcp.22783.

12. Cesari M., Pahor M., Incalzi R.A. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther. 2010;28(5):72-91. doi: 10.1111/j.1755-5922.2010.00171.

13. Oishi K. Plasminogen activator inhibitor-1 and the circadian clock in metabolic disorders. Clin Exp Hypertens. 2009;31(3):208-19. doi: 10.1080/10641960902822468.

14. Hamaguchi M., Takeda N., Kojima T., Ohbora A., Kato T., Sarui H. et al. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol. 2012;18(13):1508-16. doi: 10.3748/wjg.v18.i13.1508.

15. Graham R.C., Burke A., Stettler N. Ethnic and sex differences in the association between metabolic syndrome and suspected nonalcoholic fatty liver disease in a nationally representative sample of US adolescents. J Pediatr Gastroenterol Nutr. 2009;49(4):442-449. doi: 10.1097/MPG.0b013e31819f73b4.

16. Castro-Martínez M.G., Banderas-Lares D.Z., Ramírez-Martínez J.C., Escobedo-de la Peña J. Prevalence of nonalcoholic fatty liver disease in subjects with metabolic syndrome. Cir Cir. 2012;80(2):128-133.

17. Tsai C.H., Li T.C., Lin C.C. Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease. South Med J. 2008;101(9):900-905. doi: 10.1097/SMJ.0b013e31817e8af9.

18. Zhang T., Zhang C., Zhang Y., Tang F., Li H., Zhang Q. et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study. Atherosclerosis. 2015;240(1):144-148. doi: 10.1016/j.atherosclerosis.2015.02.049.

19. Tilg H., Moschen A.R., Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32-42. doi: 10.1038/nrgastro.2016.147.

20. Rhee E.J. Nonalcoholic fatty liver disease and diabetes: An epidemiological perspective. Endocrinol Metab (Seoul). 2019;34:226-233. doi: 10.3803/EnM.2019.34.3.226.

21. En Li Cho E, Ang C.Z., Quek J., Fu C.E., Lim L.K., Heng Z.E. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138-2148. doi: 10.1136/gutjnl-2023-330110.

22. Quek J., Chan K.E., Wong Z.Y., Tan C., Tan B., Lim W.H., et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X.

23. Afrin S., Gasparrini M., Forbes-Hernández T.Y. Protective effects of manuka honey on LPS-treated RAW 264.7 macrophages. Part 1: Enhancement of cellular viability, regulation of cellular apoptosis and improvement of mitochondrial functionality. Food Chem Toxicol. 2018;121:203-213.

24. Gasparrini M., Afrin S., Forbes-Hernández T.Y. Protective effects of manuka honey on LPS-treated RAW 264.7 macrophages. Part 2: Control of oxidative stress induced damage, increase of antioxidant enzyme activities and attenuation of inflammation. Food Chem Toxicol. 2018;120:578-587.

25. Alvarez-Suarez J.M., Giampieri F., Battino M. Honey as a source of dietary antioxidants: structures, bioavailability and evidence of protective effects against human chronic diseases. Curr Med Chem. 2013;20:621-638.

26. Ahmed A., Tul-Noor Z., Lee D., Bajwah S., Ahmed Z., Zafar S., et al. Effect of honey on cardiometabolic risk factors: a systematic review and meta-analysis. Nutr Rev. 2023;81(7):758-774. doi: 10.1093/nutrit/nuac086.

27. Pasupuleti V.R., Arigela C.S., Gan S.H., Salam S.K.N., Krishnan K.T., Rahman N.A., et al. A Review on Oxidative Stress, Diabetic Complications, and the Roles of Honey Polyphenols. Oxid Med Cell Longev. 2020;11:1-16. doi: 10.1155/2020/8878172.